HUE038811T2 - Új RIG-I ligandumok és eljárás elõállításukra - Google Patents

Új RIG-I ligandumok és eljárás elõállításukra

Info

Publication number
HUE038811T2
HUE038811T2 HUE13774100A HUE13774100A HUE038811T2 HU E038811 T2 HUE038811 T2 HU E038811T2 HU E13774100 A HUE13774100 A HU E13774100A HU E13774100 A HUE13774100 A HU E13774100A HU E038811 T2 HUE038811 T2 HU E038811T2
Authority
HU
Hungary
Prior art keywords
ligands
producing
methods
novel rig
rig
Prior art date
Application number
HUE13774100A
Other languages
English (en)
Inventor
Marion Goldeck
Den Boorn Jasper Van
Janos Ludwig
Christine Schuberth-Wagner
Original Assignee
Univ Bonn Rheinische Friedrich Wilhelms
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Bonn Rheinische Friedrich Wilhelms filed Critical Univ Bonn Rheinische Friedrich Wilhelms
Publication of HUE038811T2 publication Critical patent/HUE038811T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C07H1/02—Phosphorylation
    • C07H1/04—Introducing polyphosphoric acid radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3517—Marker; Tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3527—Other alkyl chain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
    • C12N2310/3533—Halogen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Insulating Materials (AREA)
  • Electric Propulsion And Braking For Vehicles (AREA)
HUE13774100A 2012-09-27 2013-09-26 Új RIG-I ligandumok és eljárás elõállításukra HUE038811T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12186444.1A EP2712870A1 (en) 2012-09-27 2012-09-27 Novel RIG-I ligands and methods for producing them

Publications (1)

Publication Number Publication Date
HUE038811T2 true HUE038811T2 (hu) 2018-11-28

Family

ID=46940404

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE13774100A HUE038811T2 (hu) 2012-09-27 2013-09-26 Új RIG-I ligandumok és eljárás elõállításukra

Country Status (32)

Country Link
US (3) US10059943B2 (hu)
EP (5) EP2712870A1 (hu)
JP (1) JP6313768B2 (hu)
KR (1) KR102182479B1 (hu)
CN (2) CN106279300B (hu)
AU (2) AU2013322620C1 (hu)
BR (2) BR122019023887B1 (hu)
CA (1) CA2885564C (hu)
CL (1) CL2015000752A1 (hu)
CY (1) CY1120660T1 (hu)
DK (1) DK2903997T3 (hu)
EA (2) EA034605B1 (hu)
ES (1) ES2679373T3 (hu)
HK (2) HK1209128A1 (hu)
HR (1) HRP20181114T1 (hu)
HU (1) HUE038811T2 (hu)
IL (1) IL237794B (hu)
LT (1) LT2903997T (hu)
MX (1) MX2015003787A (hu)
NZ (2) NZ736108A (hu)
PH (1) PH12015500644A1 (hu)
PL (1) PL2903997T3 (hu)
PT (1) PT2903997T (hu)
RS (1) RS57609B1 (hu)
SA (2) SA517380700B1 (hu)
SG (3) SG11201501961PA (hu)
SI (1) SI2903997T1 (hu)
TN (1) TN2015000104A1 (hu)
TR (1) TR201810231T4 (hu)
UA (1) UA117565C2 (hu)
WO (1) WO2014049079A1 (hu)
ZA (1) ZA201501718B (hu)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008017473A2 (en) 2006-08-08 2008-02-14 Gunther Hartmann Structure and use of 5' phosphate oligonucleotides
JP5689413B2 (ja) 2008-05-21 2015-03-25 ライニッシュ フリードリッヒ−ウィルヘルムズ−ユニバーシタット ボン 平滑末端を有する５’三リン酸オリゴヌクレオチドおよびその使用
EP2508530A1 (en) 2011-03-28 2012-10-10 Rheinische Friedrich-Wilhelms-Universität Bonn Purification of triphosphorylated oligonucleotides using capture tags
EP2712870A1 (en) 2012-09-27 2014-04-02 Rheinische Friedrich-Wilhelms-Universität Bonn Novel RIG-I ligands and methods for producing them
US9861574B2 (en) * 2013-04-09 2018-01-09 Duke University 2-fluoro-modified RNAs as immunostimulators
DE102015008536A1 (de) 2015-07-02 2017-01-05 Rheinische Friedrich-Wilhelms-Universität Bonn Diskontinuierliche Oligonukleotid-Liganden
EP3600342B1 (en) 2017-03-24 2021-06-23 Rigontec GmbH Method for designing rig-i ligands
WO2018187328A1 (en) 2017-04-03 2018-10-11 Duke University Compositions and methods for differential induction of cell death and interferon expression
CN112105733A (zh) 2018-04-19 2020-12-18 查美特制药公司 合成rig-i样受体激动剂
EP3781687A4 (en) * 2018-04-20 2022-02-09 Merck Sharp & Dohme Corp. NEW RIG-I SUBSTITUTED AGONISTS: COMPOSITIONS AND METHODS THEREOF
KR20210018267A (ko) 2018-05-07 2021-02-17 알닐람 파마슈티칼스 인코포레이티드 간외 전달
KR102373488B1 (ko) * 2019-02-22 2022-03-14 주식회사 레모넥스 면역활성 또는 암의 예방 또는 치료용 의약 조성물
WO2020260547A1 (en) 2019-06-27 2020-12-30 Rigontec Gmbh Design method for optimized rig-i ligands
IL309662A (en) 2021-07-02 2024-02-01 Univ Yale Compositions and methods for treating cancer
WO2023034864A1 (en) 2021-08-31 2023-03-09 Yale University Compositions and methods for treating cancers
US20230303719A1 (en) 2022-03-03 2023-09-28 Yale University Humanized 3e10 antibodies, variants, and antigen binding fragments thereof

Family Cites Families (220)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3534017A (en) 1967-03-14 1970-10-13 Kyowa Hakko Kogyo Kk Process for the preparation of nucleoside-5'-diphosphates and triphosphates and mono- and oligo-nucleotidyl-nucleoside-5'-diphosphates and triphosphates
US4210746A (en) 1978-08-10 1980-07-01 National Research Development Corporation Nucleotide inhibitor of protein synthesis
US4285605A (en) 1979-07-02 1981-08-25 International Business Machines Corporation Escapement mechanism and backspace mechanism for a moving paper carriage typewriter having dual pitch capability
FR2471785A1 (fr) 1979-12-21 1981-06-26 Fabre Sa Pierre Preparations immunostimulantes a base d'arn ribosomaux et procede de preparation des arn
DE3023787A1 (de) 1980-06-25 1982-01-21 Studiengesellschaft Kohle mbH, 4330 Mülheim Verfahren zur erhoehung der inkorporation und der expression von genetischem material in die kerne von intakten zellen mit hilfe von liposomen
EP0081099A3 (en) 1981-12-04 1983-08-10 Sloan-Kettering Institute For Cancer Research Capped oligonucleotide anti-viral agents
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5194428A (en) 1986-05-23 1993-03-16 Worcester Foundation For Experimental Biology Inhibition of influenza virus replication by oligonucleotide phosphorothioates
US5264423A (en) 1987-03-25 1993-11-23 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
EP0402402B1 (en) 1988-02-26 1995-12-27 Worcester Foundation For Biomedical Research, Inc. Inhibition of htlv-iii by exogenous oligonucleotides
DE68929361T2 (de) 1988-04-27 2002-06-20 Isis Pharmaceuticals Inc Oligoribonukleotid-Derivate und Verwendung davon als Antiviral Arzneimittel
JP2976436B2 (ja) 1988-04-27 1999-11-10 味の素株式会社 新規オリゴリボヌクレオチド誘導体及び抗ウイルス剤への使用
DE3907562A1 (de) 1989-03-09 1990-09-13 Bayer Ag Antisense-oligonukleotide zur inhibierung der transaktivatorzielsequenz (tar) und der synthese des transaktivatorproteins (tat) aus hiv-1 und deren verwendung
EP0472648A4 (en) 1989-05-18 1992-09-16 Microprobe Corporation Crosslinking oligonucleotides
US5134066A (en) 1989-08-29 1992-07-28 Monsanto Company Improved probes using nucleosides containing 3-dezauracil analogs
DK0452457T3 (da) 1989-11-03 1998-03-02 Univ Vanderbilt Fremgangsmåde til in vivo fjernelse af funktionelle fremmede gener
WO1994002501A1 (en) 1992-07-23 1994-02-03 Isis Pharmaceuticals, Inc. Novel 2'-o-alkyl nucleosides and phosphoramidites processes for the preparation and uses thereof
US5149797A (en) 1990-02-15 1992-09-22 The Worcester Foundation For Experimental Biology Method of site-specific alteration of rna and production of encoded polypeptides
JPH05501060A (ja) 1990-03-21 1993-03-04 アイシス・ファーマシューティカルス・インコーポレーテッド Ｒｎａ模倣による遺伝子発現活性変調のための試薬および方法
US5292875A (en) 1990-04-20 1994-03-08 Lynx Therapeutics, Inc. Method of synthesizing sulfurized oligonucleotide analogs
US5166195A (en) 1990-05-11 1992-11-24 Isis Pharmaceuticals, Inc. Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides
NZ239252A (en) 1990-08-09 1997-07-27 Genta Inc Reagent for attaching a psoralen-containing moiety to an oligonucleotide(derivative); oligonucleotide(derivative)-psoralen conjugates
BR9106747A (pt) 1990-08-14 1993-07-20 Isis Pharmaceuticals Inc Oligonucleotideo ou analogo de oligonucleotideo e processo para tratamento de um animal suspeito de estar infectado por virus da influenza
US5271941A (en) 1990-11-02 1993-12-21 Cho Chung Yoon S Antisense oligonucleotides of human regulatory subunit RI.sub.α of cAMP-dependent protein kinases
AU661490B2 (en) 1991-03-27 1995-07-27 Research Corporation Technologies, Inc. Single-stranded circular oligonucleotides
DE4110085A1 (de) 1991-03-27 1992-10-01 Boehringer Ingelheim Int 2'-o-alkyl-oligoribonukleotide, verfahren zu deren herstellung und deren verwendung als antisense-oligonukleotide
US5646267A (en) 1991-08-05 1997-07-08 Polish Academy Of Sciences Method of making oligonucleotides and oligonucleotide analogs using phospholanes and enantiomerically resolved phospholane analogues
US7119184B2 (en) 1991-08-12 2006-10-10 Isis Pharmaceuticals, Inc. Oligonucleotides having A-DNA form and B-DNA form conformational geometry
US6369209B1 (en) 1999-05-03 2002-04-09 Isis Pharmaceuticals, Inc. Oligonucleotides having A-DNA form and B-DNA form conformational geometry
ATE221127T1 (de) 1991-10-15 2002-08-15 Isis Pharmaceuticals Inc Über chirale phosphoratome gebundene oligonukleotide
NZ244820A (en) 1991-10-25 1994-01-26 Isis Pharmaceuticals Inc Oligonucleotide inhibitor of epstein-barr virus.
FR2685346B1 (fr) 1991-12-18 1994-02-11 Cis Bio International Procede de preparation d'arn double-brin, et ses applications.
US5644048A (en) 1992-01-10 1997-07-01 Isis Pharmaceuticals, Inc. Process for preparing phosphorothioate oligonucleotides
CA2135646A1 (en) 1992-05-11 1993-11-25 Kenneth G. Draper Method and reagent for inhibiting viral replication
US5606049A (en) 1992-06-03 1997-02-25 Genta Incorporated Method of preparing 2'-O-methyl cytidine monomers useful in oligomer synthesis
US5652355A (en) 1992-07-23 1997-07-29 Worcester Foundation For Experimental Biology Hybrid oligonucleotide phosphorothioates
US6346614B1 (en) 1992-07-23 2002-02-12 Hybridon, Inc. Hybrid oligonucleotide phosphorothioates
TW244371B (hu) 1992-07-23 1995-04-01 Tri Clover Inc
IL108206A0 (en) 1993-01-06 1994-04-12 Univ Johns Hopkins Oligomers having improved stability at acid ph
CA2154578A1 (en) 1993-01-25 1994-08-04 Ekambar R. Kandimalla Oligonucleotide alkylphosphonates and alkylphosphonothioates
EP0695306A1 (en) 1993-04-19 1996-02-07 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified purines
FR2705099B1 (fr) 1993-05-12 1995-08-04 Centre Nat Rech Scient Oligonucléotides phosphorothioates triesters et procédé de préparation.
WO1995003406A2 (en) 1993-07-19 1995-02-02 Gen-Probe Incorporated Enhancement of oligonucleotide inhibition of protein production, cell proliferation, and/or multiplication of infectious disease pathogens
JPH0799976A (ja) 1993-09-30 1995-04-18 Takeda Chem Ind Ltd 修飾オリゴヌクレオチド
US5801235A (en) 1994-05-25 1998-09-01 Hybridon, Inc. Oligonucleotides with anti-cytomegalovirus activity
AU2591495A (en) 1994-05-27 1995-12-21 Hybridon, Inc. Use of oligonucleotide phosphorothioate for depleting complement and for reducing blood pressure
US5866699A (en) 1994-07-18 1999-02-02 Hybridon, Inc. Oligonucleotides with anti-MDR-1 gene activity
ATE202569T1 (de) 1994-09-07 2001-07-15 Hybridon Inc Prodrug-oligonukleotide
US5591721A (en) 1994-10-25 1997-01-07 Hybridon, Inc. Method of down-regulating gene expression
JPH08154687A (ja) 1994-12-12 1996-06-18 Yamanouchi Pharmaceut Co Ltd アンチセンスオリゴヌクレオチド及び抗ウイルス剤
WO1996018736A2 (en) 1994-12-13 1996-06-20 Ribozyme Pharmaceuticals, Inc. Method and reagent for treatment of arthritic conditions, induction of graft tolerance and reversal of immune responses
CA2208528A1 (en) 1994-12-22 1996-06-27 Hybridon, Inc. Synthesis of stereospecific oligonucleotide phosphorothioates
US6111095A (en) 1995-06-07 2000-08-29 Merck & Co., Inc. Capped synthetic RNA, analogs, and aptamers
GB9511720D0 (en) 1995-06-09 1995-08-02 Isis Innovation Oligonucleotide phosphorylation method and products
US20040234999A1 (en) 1996-04-02 2004-11-25 Farrar Gwenyth Jane Genetic suppression and replacement
US6127535A (en) 1997-11-05 2000-10-03 Ribozyme Pharmaceuticals, Inc. Nucleoside triphosphates and their incorporation into oligonucleotides
EP1626086A2 (en) 1998-04-20 2006-02-15 Ribozyme Pharmaceuticals, Inc. Double-stranded nucleic acid molecules with novel chemical compositions capable of modulating gene expression
EP1493818A3 (en) 1998-04-29 2006-02-15 Ribozyme Pharmaceuticals, Inc. Nucleoside triphosphates and their incorporation into ribozymes
WO1999055857A2 (en) 1998-04-29 1999-11-04 Ribozyme Pharmaceuticals, Inc. Nucleoside triphosphates and their incorporation into ribozymes
US6562798B1 (en) 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
US6344323B1 (en) 1998-09-16 2002-02-05 Vitagenix, Inc. Compositions and methods for inhibiting cox-2 expression and treating cox-2 associated disorders by using cox-2 antisense oligonucleotides
WO2001016312A2 (en) 1999-08-31 2001-03-08 Ribozyme Pharmaceuticals, Inc. Nucleic acid based modulators of gene expression
AU783118B2 (en) 1999-09-27 2005-09-29 Coley Pharmaceutical Gmbh Methods related to immunostimulatory nucleic acid-induced interferon
US20020028784A1 (en) 2000-03-10 2002-03-07 Nest Gary Van Methods of preventing and treating viral infections using immunomodulatory polynucleotide sequences
DE10013600A1 (de) 2000-03-18 2002-01-10 Aventis Res & Tech Gmbh & Co Reaktive Monomere für die Oligonucleotid- und Polynucleotidsynthese, modifizierte Oligonucleotide und Polynucleotiden und ein Verfahren zu deren Herstellung
US6686461B1 (en) 2000-03-22 2004-02-03 Solulink Bioscience, Inc. Triphosphate oligonucleotide modification reagents and uses thereof
EP1247815A3 (en) 2001-03-25 2003-01-29 Exiqon A/S Modified oligonucleotides and uses thereof
US6900308B2 (en) 2001-07-16 2005-05-31 Isis Pharmaceuticals, Inc. α-modified nucleoside triphosphates
AU2002329667A1 (en) 2001-07-30 2003-02-17 Uta Griesenbach Specific inhibition of gene expression by small double stranded rnas
FR2832154B1 (fr) 2001-11-09 2007-03-16 Centre Nat Rech Scient Oligonucleotides inhibiteurs et leur utilisation pour reprimer specifiquement un gene
US20030203868A1 (en) 2002-02-06 2003-10-30 Bushman Frederic D. Inhibition of pathogen replication by RNA interference
AU2003217863B9 (en) 2002-02-28 2009-10-29 Biota Scientific Management Pty Ltd Nucleotide mimics and their prodrugs
JP2005526778A (ja) 2002-03-15 2005-09-08 アストラル，インコーポレイテッド 免疫調節性非コードｒｎａモチーフを用いて抗体及び主要組織適合性クラスｉ拘束性又はクラスｉｉ拘束性ｔ細胞の応答を開始或いは増強させるための組成物及び方法
CA2480775C (en) 2002-04-04 2016-05-31 Coley Pharmaceutical Gmbh Immunostimulatory g,u-containing oligoribonucleotides
MXPA04010282A (es) 2002-04-18 2005-08-18 Acuity Pharmaceuticals Inc Medios y metodos para la inhibicion especifica de genes en celulas y tejido de cns y/u ojo.
WO2003091433A1 (fr) 2002-04-26 2003-11-06 National Institute Of Advanced Industrial Science And Technology Systeme d'expression pour molecule d'arn a tige-boucle ayant un effet d'arni
CA2388049A1 (en) 2002-05-30 2003-11-30 Immunotech S.A. Immunostimulatory oligonucleotides and uses thereof
EP1552018B1 (en) 2002-08-12 2009-07-01 New England Biolabs, Inc. Methods and compositions relating to gene silencing
US7109316B2 (en) 2002-08-23 2006-09-19 Ce Healthcare Bio-Sciences Corp. Oligonucleotide tagged nucleoside triphosphates (OTNTPs) for genetic analysis
WO2004022777A1 (en) 2002-09-04 2004-03-18 Johnson & Johnson Research Pty Ltd METHODS USING dsDNA TO MEDIATE RNA INTERFERENCE (RNAi)
US20120045390A1 (en) 2002-09-11 2012-02-23 Genentech, Inc. Composition and Methods for the Diagnosis and Treatment of Tumor
JP2006507841A (ja) 2002-11-14 2006-03-09 ダーマコン， インコーポレイテッド 機能的ｓｉＲＮＡおよび超機能的ｓｉＲＮＡ
US7250496B2 (en) 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
US7696334B1 (en) 2002-12-05 2010-04-13 Rosetta Genomics, Ltd. Bioinformatically detectable human herpesvirus 5 regulatory gene
US20130130231A1 (en) 2002-11-26 2013-05-23 Isaac Bentwich Bioinformatically detectable group of novel viral regulatory genes and uses thereof
US7790867B2 (en) 2002-12-05 2010-09-07 Rosetta Genomics Inc. Vaccinia virus-related nucleic acids and microRNA
CA2511907A1 (en) 2003-01-06 2004-07-22 Wyeth Compositions and methods for diagnosing and treating colon cancers
WO2004074441A2 (en) 2003-02-19 2004-09-02 Government Of The United States Of America Represented By The Secretary Department Of Health And Human Services Amplification or overexpression of mll septin-like fusion (msf) and septin9 and methods related thereto
CN1176937C (zh) 2003-02-21 2004-11-24 复旦大学附属中山医院 一种双链rna及其用途
US20040261149A1 (en) 2003-02-24 2004-12-23 Fauquet Claude M. siRNA-mediated inhibition of gene expression in plant cells
US7381410B2 (en) 2003-03-12 2008-06-03 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
AU2004220525B2 (en) 2003-03-12 2011-03-31 Vasgene Therapeutics, Inc. Nucleic acid compounds for inhibiting angiogenesis and tumor growth
EP2141234B1 (en) 2003-03-21 2016-04-27 Roche Innovation Center Copenhagen A/S Short Interfering RNA (siRNA) Analogues
US20040220130A1 (en) 2003-03-24 2004-11-04 Robbins Paul D. Compact synthetic expression vector comprising double-stranded DNA molecules and methods of use thereof
US8969543B2 (en) 2003-04-03 2015-03-03 Bioneer Corporation SiRNA-hydrophilic polymer conjugates for intracellular delivery of siRNA and method thereof
US20050042641A1 (en) 2003-05-27 2005-02-24 Cold Spring Harbor Laboratory In vivo high throughput selection of RNAi probes
JP2006526394A (ja) 2003-06-03 2006-11-24 ベニテック オーストラリア リミテッド 二本鎖核酸
US20060166914A1 (en) 2003-06-06 2006-07-27 Dainippon Sumitomo Pharma Co., Ltd Method of nucleic acid infusion
JP4874801B2 (ja) 2003-06-11 2012-02-15 イデラ ファーマシューティカルズ インコーポレイテッド 安定化免疫調節オリゴヌクレオチド
FR2857013B1 (fr) 2003-07-02 2005-09-30 Commissariat Energie Atomique Petits arn interferents specifiques des sous-unites alpha, alpha prime et beta de la proteine kinase ck2 et leurs applications
US8034619B2 (en) 2003-12-19 2011-10-11 University Of Cincinnati Polyamides for nucleic acid delivery
EP1747284A4 (en) 2004-02-06 2009-03-11 Wyeth Corp DIAGNOSTICS AND THERAPEUTICS OF CANCER
US20050182005A1 (en) 2004-02-13 2005-08-18 Tuschl Thomas H. Anti-microRNA oligonucleotide molecules
US20070265220A1 (en) 2004-03-15 2007-11-15 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
US8084599B2 (en) 2004-03-15 2011-12-27 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
US20060035815A1 (en) 2004-05-04 2006-02-16 Nastech Pharmaceutical Company Inc. Pharmaceutical compositions for delivery of ribonucleic acid to a cell
WO2005117991A2 (en) 2004-05-04 2005-12-15 Nastech Pharmaceutical Company Inc. Compositions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells
EP1745131A2 (en) 2004-05-12 2007-01-24 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. METHOD TO INDUCE RNAi IN PROKARYOTIC ORGANISMS
CA2572439A1 (en) 2004-07-02 2006-01-12 Protiva Biotherapeutics, Inc. Immunostimulatory sirna molecules and uses therefor
JPWO2006016574A1 (ja) 2004-08-12 2008-05-01 国立大学法人 熊本大学 ＲＮＡｉを利用した抗腫瘍剤
ATE505540T1 (de) 2004-11-16 2011-04-15 Qiagen Gmbh Genabschaltung (gene silencing) durch hybride sens-dna und antisens-rna konstrukte, gekoppelt an ein peptid zur erleichterten aufnahme in zellen
AU2005313883B2 (en) 2004-12-09 2011-03-31 Alnylam Pharmaceuticals, Inc. Compositions and methods for inducing an immune response in a mammal and methods of avoiding an immune response to oligonucleotide agents such as short interfering RNAs
WO2006074400A2 (en) 2005-01-07 2006-07-13 State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Method to trigger rna interference
WO2006078646A2 (en) 2005-01-18 2006-07-27 Caltagirone Gaetano T A class of supramolecular drug molecules and methods of identification and use thereof
US20060178334A1 (en) 2005-02-04 2006-08-10 City Of Hope Double-stranded and single-stranded RNA molecules with 5 ' triphosphates and their use for inducing interferon
WO2006083042A1 (ja) 2005-02-07 2006-08-10 Takeda Pharmaceutical Company Limited 神経変性疾患の予防・治療剤
JP4645234B2 (ja) 2005-03-03 2011-03-09 和光純薬工業株式会社 架橋剤、それを用いた架橋方法、遺伝子発現調節方法および遺伝子機能調査方法
ES2381201T3 (es) 2005-03-31 2012-05-24 Calando Pharmaceuticals, Inc. Inhibidores de la subunidad 2 de la ribonucleótido-reductasa y utilizaciones de los mismos
US7893244B2 (en) 2005-04-12 2011-02-22 Intradigm Corporation Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases
JP2008537752A (ja) 2005-04-12 2008-09-25 イントラディグム コーポレイション がんおよび他の新血管形成疾患を処置するためのＲＮＡｉ治療用の組成物および方法
US20070066521A1 (en) 2005-04-13 2007-03-22 Fauquet Claude M Short RNA-binding proteins
WO2006119643A1 (en) 2005-05-12 2006-11-16 Replicor Inc. Anti-ocular angiogenesis molecules and their uses
WO2006122409A1 (en) 2005-05-16 2006-11-23 Replicor Inc. Antimicrobial molecules and their uses
CN101213300B (zh) 2005-06-01 2013-01-23 聚加转染股份有限公司 用于rna干扰的寡核苷酸及其生物学应用
WO2006130949A1 (en) 2005-06-08 2006-12-14 Replicor Inc. Anti amyloid-related disease molecules and their uses
CN101273130B (zh) 2005-07-07 2012-05-30 耶路撒冷希伯来大学伊森姆研究发展公司 用于下调h19的核酸物质及其使用方法
CN101287835A (zh) 2005-08-17 2008-10-15 株式会社百奥尼 用于siRNA细胞内输送的siRNA-亲水性聚合物结合物及其方法
JP2009507852A (ja) 2005-09-08 2009-02-26 エムディーアールエヌエー，インコーポレイテッド リボ核酸の細胞への送達用医薬組成物
US8076068B2 (en) 2005-09-14 2011-12-13 Gunther Hartmann Method for determining immunostimulatory activity of RNA oligonucleotides
EP1764107A1 (en) 2005-09-14 2007-03-21 Gunther Hartmann Compositions comprising immunostimulatory RNA oligonucleotides and methods for producing said RNA oligonucleotides
WO2007107304A2 (en) 2006-03-17 2007-09-27 Novosom Ag An efficient method for loading amphoteric liposomes with nucleic acid active substances
WO2007038788A2 (en) 2005-09-29 2007-04-05 The Cleveland Clinic Foundation Small interfering rnas as non-specific drugs
WO2007051303A1 (en) 2005-11-02 2007-05-10 Protiva Biotherapeutics, Inc. MODIFIED siRNA MOLECULES AND USES THEREOF
EP1957648B1 (en) 2005-11-17 2014-04-23 Board of Regents, The University of Texas System Modulation of gene expression by oligomers targeted to chromosomal dna
JP2009519339A (ja) 2005-12-12 2009-05-14 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 筋細胞増殖及び分化を調節するマイクロｒｎａ
WO2007080457A2 (en) 2005-12-30 2007-07-19 Institut Gustave Roussy Use of inhibitors of scinderin and/or of ephrin-a1 for treating tumors
CN101460178B (zh) 2006-04-07 2016-12-07 艾德拉药物股份有限公司 用于tlr7和tlr8的稳定化的免疫调节性rna(simra)化合物
ATE502122T1 (de) 2006-06-01 2011-04-15 Trilink Biotechnologies Chemisch modifizierte oligonukleotidprimer zur nukleinsäureamplifikation
US20080091005A1 (en) 2006-07-20 2008-04-17 Visigen Biotechnologies, Inc. Modified nucleotides, methods for making and using same
WO2008014979A2 (en) 2006-07-31 2008-02-07 Curevac Gmbh NUCLEIC ACID OF FORMULA (I): GIXmGn, OR (II): CIXmCn, IN PARTICULAR AS AN IMMUNE-STIMULATING AGENT/ADJUVANT
WO2008017473A2 (en) 2006-08-08 2008-02-14 Gunther Hartmann Structure and use of 5' phosphate oligonucleotides
EP1920775B1 (en) 2006-10-10 2012-12-19 Gunther Prof. Dr. Hartmann 5'Triphosphate oligonucleotide induces anti-viral response
JP5407862B2 (ja) 2006-10-04 2014-02-05 サントル・ナシオナル・ドゥ・ラ・ルシェルシュ・シアンティフィーク（セーエヌエールエス） ｓｉＲＮＡおよび脂質性４，５−二置換２−デオキシストレプタミン環アミノグリコシド誘導体を含む組成物ならびにその用途
WO2008045576A2 (en) 2006-10-12 2008-04-17 Yijia Liu Compositions and methods of rnai therapeutics for treatment of cancer and other neovascularization diseases
CN101190944A (zh) 2006-12-01 2008-06-04 北京诺赛基因组研究中心有限公司 人类新细胞因子及其用途
WO2008080091A2 (en) 2006-12-21 2008-07-03 Vical Incorporated Activation of rig-i pathway
CN101583715A (zh) 2006-12-21 2009-11-18 因特拉迪格姆公司 用于治疗癌症的抑制性多核苷酸组合物和方法
US7858772B2 (en) 2006-12-22 2010-12-28 Roche Molecular Systems, Inc. Compounds and methods for synthesis and purification of oligonucleotides
WO2008087641A2 (en) 2007-01-16 2008-07-24 Yissum Research Development Company Of The Hebrew University Of Jerusalem H19 silencing nucleic acid agents for treating rheumatoid arthritis
US9249423B2 (en) 2007-02-02 2016-02-02 Yale University Method of de-differentiating and re-differentiating somatic cells using RNA
WO2008099396A1 (en) 2007-02-15 2008-08-21 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of h19-silencing nucleic acid agents for treating restenosis
EP2113565A4 (en) 2007-02-19 2010-08-18 Univ Kyoto CONDUCTIVE SUBSTRATE FOR NUCLEIC ACID RELIEF AND NUCLEIC ACID RELIEF PROCESS
MY173854A (en) 2007-03-13 2020-02-25 Malaysian Palm Oil Board Expression regulatory elements
WO2008124165A2 (en) 2007-04-09 2008-10-16 Chimeros, Inc. Self-assembling nanoparticle drug delivery system
CN101088565A (zh) 2007-04-17 2007-12-19 华东师范大学 miRNA－34a的用途
CN101289486B (zh) * 2007-04-18 2012-05-30 上海吉凯基因化学技术有限公司 一种合成rna单体的方法
WO2008134593A1 (en) 2007-04-25 2008-11-06 President And Fellows Of Harvard College Molecular circuits
CA3165250A1 (en) 2007-05-01 2008-11-06 Santaris Pharma A/S Splice switching oligomers for tnf superfamily receptors and their use in treatment of disease
WO2008153733A2 (en) 2007-05-29 2008-12-18 Nature Technology Corporation Vectors and methods for genetic immunization
EP2178896A1 (en) 2007-07-31 2010-04-28 The Johns Hopkins University Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders
US8367815B2 (en) 2007-08-28 2013-02-05 California Institute Of Technology Modular polynucleotides for ligand-controlled regulatory systems
US20110082185A1 (en) 2007-09-17 2011-04-07 Ludwig Institute For Cancer Research Ltd. Cancer-testis gene silencing agents and uses thereof
US20100239578A1 (en) 2007-10-11 2010-09-23 University Health Network Modulation of sirp-alpha - cd47 interaction for increasing human hematopoietic stem cell engraftment and compounds therefor
CA2702039A1 (en) 2007-10-12 2009-04-23 Intradigm Corporation Therapeutic sirna molecules for reducing vegfr1 expression in vitro and in vivo
DE102007052114B4 (de) 2007-10-30 2011-01-05 T2Cure Gmbh Verfahren zur Modulation der Funktion, des Wachstums oder der Differenzierung einer Zelle
EP2217705A2 (en) 2007-11-05 2010-08-18 Baltic Technology Development, Ltd. Use of oligonucleotides with modified bases in hybridization of nucleic acids
ES2530215T3 (es) 2007-11-06 2015-02-27 Adiutide Pharmaceuticals Gmbh Análogos de oligorribonucleótidos inmunoestimulantes que contienen restos de oligofosfato modificados
US8735567B2 (en) 2007-11-06 2014-05-27 Patrick Y. Lu Multi-targeted RNAi therapeutics for scarless wound healing of skin
AU2008321253B2 (en) 2007-11-12 2014-01-16 Masaryk Memorial Cancer Institute Therapeutic applications of p53 isoforms in regenerative medicine, aging and cancer
US8357501B2 (en) 2007-11-29 2013-01-22 Molecular Health Gmbh Tissue protective erythropoietin receptor (NEPOR) and methods of use
PT2492355E (pt) 2007-11-29 2015-09-10 Molecular Health Gmbh Recetor de eritropoietina protetora de tecido (nepor) e métodos de utilização
GB0725321D0 (en) 2007-12-31 2008-02-06 Syntaxin Ltd Delivery vehicles
SG188104A1 (en) 2008-01-31 2013-03-28 Curevac Gmbh Nucleic acids comprising formula (nuglxmgnnv)a and derivatives thereof as an immunostimulating agents /adjuvants
JP5689413B2 (ja) * 2008-05-21 2015-03-25 ライニッシュ フリードリッヒ−ウィルヘルムズ−ユニバーシタット ボン 平滑末端を有する５’三リン酸オリゴヌクレオチドおよびその使用
PL2518150T3 (pl) 2008-05-21 2016-02-29 Univ Bonn Rheinische Friedrich Wilhelms Oligonukleotyd 5' trifosforanowy z tępym końcem i jego zastosowania
CA2635187A1 (en) 2008-06-05 2009-12-05 The Royal Institution For The Advancement Of Learning/Mcgill University Oligonucleotide duplexes and uses thereof
US20110152352A1 (en) 2008-06-10 2011-06-23 Tufts University Smad proteins control drosha-mediated mirna maturation
CN101632833B (zh) 2008-07-25 2013-11-06 上海市计划生育科学研究所 一种前列腺癌相关的基因及其用途
WO2011028218A1 (en) * 2009-09-02 2011-03-10 Alnylam Pharmaceuticals, Inc. Process for triphosphate oligonucleotide synthesis
AU2009288078B2 (en) * 2008-09-02 2014-10-30 Alnylam Pharmaceuticals, Inc. Synthetic methods and derivatives of triphosphate oligonucleotides
WO2010042749A2 (en) 2008-10-08 2010-04-15 Chimeros Inc. Chimeric therapeutics, compositions, and methods for using same
WO2010042755A2 (en) 2008-10-08 2010-04-15 Chimeros Inc. Chimeric therapeutics, compositions, and methods for using same
WO2010042742A2 (en) 2008-10-08 2010-04-15 Chimeros Inc. Chimeric therapeutics, compositions, and methods for using same
WO2010042751A2 (en) 2008-10-08 2010-04-15 Chimeros Inc. Chimeric therapeutics, compositions, and methods for using same
JP4936343B6 (ja) 2008-10-23 2018-06-27 国立大学法人 東京大学 ｍｉｃｒｏＲＮＡの機能阻害法
WO2010062502A1 (en) 2008-11-03 2010-06-03 University Of Utah Research Foundation Carriers for the delivery of nucleic acids to cells and methods of use thereof
WO2010099161A1 (en) 2009-02-26 2010-09-02 The Ohio State University Research Foundation Micrornas in never-smokers and related materials and methods
US8987222B2 (en) 2009-04-08 2015-03-24 University Of Massachusetts Single nucleotide polymorphism (SNP) targeting therapies for the treatment of huntington'S disease
WO2010120874A2 (en) 2009-04-14 2010-10-21 Chimeros, Inc. Chimeric therapeutics, compositions, and methods for using same
US20100323018A1 (en) 2009-06-17 2010-12-23 Massachusetts Institute Of Technology Branched DNA/RNA monomers and uses thereof
ES2386855T3 (es) 2009-07-09 2012-09-03 Marina Biotech, Inc. Emulación de estructuras de lipoproteínas
US9238811B2 (en) 2009-07-14 2016-01-19 Northeastern University siRNA phospholipid conjugate
JP2013500265A (ja) 2009-07-23 2013-01-07 ザ トラスティーズ オブ プリンストン ユニバーシティ 抗ウイルス剤として用いられるｍＴＯＲキナーゼ阻害剤
WO2011028128A1 (en) * 2009-09-01 2011-03-10 Askim Frukt- Og Bærpresseri As Method to prevent oxidation of components in oil, and method to reduce the use of ethoxyquin to prevent oxidation of components in oil
EP2327783A1 (en) 2009-11-27 2011-06-01 Universitätsklinikum Freiburg Pharmaceutical composition comprising miRNA-100 and its use in the modulation of blood vessel growth
DE202009015670U1 (de) 2009-11-30 2011-04-14 Mcairlaid's Vliesstoffe Gmbh & Co. Kg Absorptionskörper zur Auflage auf Wunden
US20110247091A1 (en) 2010-03-26 2011-10-06 The Governors Of The University Of Alberta Transgenic Cells and Chickens Expressing RIG-I
WO2011133559A2 (en) 2010-04-19 2011-10-27 University Of Georgia Research Foundation, Inc. Alpha tubulin acetyltransferase
EP2385120A1 (en) 2010-05-04 2011-11-09 Justus-Liebig- Universitat Giessen Use of anti-miRNA antisense oligonucleotides for the treatment of pulmonary hypertension
US9642873B2 (en) 2010-05-04 2017-05-09 Sirnaomics, Inc. Combinations of TGFβ and COX-2 inhibitors and methods for their therapeutic application
CN101974529B (zh) 2010-09-21 2013-04-03 南京大学（苏州）高新技术研究院 含自由三磷酸基团的TGF-β特异性siRNA及其应用
WO2012056440A1 (en) 2010-10-28 2012-05-03 Nanodoc Ltd. COMPOSITIONS AND METHODS FOR ACTIVATING EXPRESSION BY A SPECIFIC ENDOGENOUS miRNA
WO2012056441A1 (en) 2010-10-28 2012-05-03 Nanodoc Ltd. Compositions and methods for specific cleavage of exogenous rna in a cell
CN102475892A (zh) 2010-11-22 2012-05-30 大连创达技术交易市场有限公司 作为制备抗癌药物的反义miRNA-210的用途
WO2012091523A2 (en) 2010-12-30 2012-07-05 Samyang Biopharmaceuticals Corporation Carrier for negatively charged drugs comprising a cationic lipid and a preparation method thereof
US8461224B2 (en) 2011-03-04 2013-06-11 National Health Research Institutes Single monomer derived linear-like copolymer comprising polyethylenimine and poly(ethylene glycol) for nucleic acid delivery
US20140212503A1 (en) 2011-03-17 2014-07-31 Hyukjin Lee Delivery system
EP2508530A1 (en) * 2011-03-28 2012-10-10 Rheinische Friedrich-Wilhelms-Universität Bonn Purification of triphosphorylated oligonucleotides using capture tags
EP2729182A4 (en) 2011-07-04 2014-12-24 Commw Scient Ind Res Org NUCLEIC COMPLEX
EP2551354A1 (en) 2011-07-25 2013-01-30 Universität Heidelberg Functionalization of RNA oligonucleotides
US20130189367A1 (en) 2011-07-29 2013-07-25 University Of Washington Through Its Center For Commercialization Nanovectors for targeted gene silencing and cytotoxic effect in cancer cells
US9579394B2 (en) 2011-08-08 2017-02-28 Universitaet Regensburg Polyanion nanocomplexes for therapeutic applications
WO2013053480A1 (de) 2011-10-11 2013-04-18 Secutech International Pte. Ltd. Zusammensetzung zur einbringung von nukleinsäuren in zellen
WO2013053481A1 (de) 2011-10-11 2013-04-18 Secutech International Pte. Ltd. Dimethylsulfoxid als lösungsmittel für nukleinsäuren
JP2014532400A (ja) 2011-10-31 2014-12-08 リボックス・ゲーエムベーハー 免疫賦活用の二本鎖ｒｎａ
JP6093775B2 (ja) 2011-11-17 2017-03-08 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 自動認識治療用ｒ／ｄｎａキメラナノ粒子（ｎｐ）
WO2013153082A1 (en) 2012-04-10 2013-10-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of nonalcoholic steatohepatitis
US20130302252A1 (en) 2012-05-11 2013-11-14 University Of Washington Through Its Center For Commercialization Polyarginine-coated magnetic nanovector and methods of use thereof
EP2712870A1 (en) * 2012-09-27 2014-04-02 Rheinische Friedrich-Wilhelms-Universität Bonn Novel RIG-I ligands and methods for producing them
US20140287023A1 (en) 2013-02-11 2014-09-25 Mcgill University 5'-triphosphate oligoribonucleotides

Also Published As

Publication number Publication date
EA201590629A1 (ru) 2016-02-29
EP3398956A1 (en) 2018-11-07
SI2903997T1 (sl) 2018-11-30
EP2963050A1 (en) 2016-01-06
IL237794B (en) 2018-12-31
EA201790916A1 (ru) 2017-08-31
BR112015006874B1 (pt) 2023-04-18
SG10201912308SA (en) 2020-02-27
SG11201501961PA (en) 2015-04-29
RS57609B1 (sr) 2018-11-30
EP2903997B1 (en) 2018-06-06
EP3398956B1 (en) 2021-11-03
TN2015000104A1 (en) 2016-06-29
BR112015006874A2 (pt) 2017-07-04
EP2903997A1 (en) 2015-08-12
WO2014049079A1 (en) 2014-04-03
HK1209128A1 (en) 2016-03-24
AU2013322620A2 (en) 2015-04-09
US20150275217A1 (en) 2015-10-01
AU2017213455A1 (en) 2017-08-24
PT2903997T (pt) 2018-07-26
AU2017213455B2 (en) 2019-02-14
US10059943B2 (en) 2018-08-28
CL2015000752A1 (es) 2015-12-04
HRP20181114T1 (hr) 2018-10-19
US20160152983A1 (en) 2016-06-02
PL2903997T3 (pl) 2018-11-30
US10072262B2 (en) 2018-09-11
NZ736108A (en) 2018-12-21
CN106279300B (zh) 2020-07-10
SA515360190B1 (ar) 2018-09-26
TR201810231T4 (tr) 2018-08-27
MX2015003787A (es) 2015-11-09
SA517380700B1 (ar) 2019-04-04
CN104703996B (zh) 2018-01-12
KR102182479B1 (ko) 2020-11-24
JP6313768B2 (ja) 2018-04-18
AU2013322620C1 (en) 2017-12-14
CA2885564A1 (en) 2014-04-03
PH12015500644B1 (en) 2015-05-11
CA2885564C (en) 2019-08-20
CY1120660T1 (el) 2019-12-11
KR20150059792A (ko) 2015-06-02
UA117565C2 (uk) 2018-08-27
JP2015532270A (ja) 2015-11-09
EP2712870A1 (en) 2014-04-02
DK2903997T3 (en) 2018-07-30
EA028707B1 (ru) 2017-12-29
NZ706443A (en) 2018-04-27
SG10201702028YA (en) 2017-04-27
BR122019023887B1 (pt) 2023-03-14
US20180312841A1 (en) 2018-11-01
PH12015500644A1 (en) 2015-05-11
HK1214602A1 (zh) 2016-07-29
AU2013322620B2 (en) 2017-08-31
EP4008722A1 (en) 2022-06-08
ES2679373T3 (es) 2018-08-24
US11142763B2 (en) 2021-10-12
CN106279300A (zh) 2017-01-04
ZA201501718B (en) 2015-12-23
AU2013322620A1 (en) 2015-04-02
CN104703996A (zh) 2015-06-10
EA034605B1 (ru) 2020-02-25
LT2903997T (lt) 2018-10-10

Similar Documents

Publication Publication Date Title
HRP20181114T1 (hr) Novi rig-i ligandi i postupci njihove proizvodnje
HK1250690A1 (zh) 方法
HK1208363A1 (en) New methods
EP2890672A4 (en) NEW PROCESS
EP2836211A4 (en) NOVEL PROCEDURE
EP2913831A4 (en) PROCESS FOR PRODUCING RARE EARTH MAGNET
EP2939754A4 (en) DRAWING FORM PROCEDURE
GB201222693D0 (en) Novel method
EP2837619A4 (en) PROCESS FOR THE PRODUCTION OF BETA-ALCOXYPROPIONAMIDE
GB2507760B (en) Methods
EP2824130A4 (en) PROCESS FOR PRODUCING POLYDIALKYLSILANE
GB201208874D0 (en) Methods
PL2914574T3 (pl) Nowy sposób
ZA201500438B (en) Method for producing microcarriers
SG11201501567QA (en) Method for producing 7-octenal
GB201204280D0 (en) Methods
EP2821391A4 (en) PROCESS FOR THE PREPARATION OF ACRYLNITRILE
EP2821390A4 (en) PROCESS FOR THE PREPARATION OF ACRYLNITRILE
IL234526A (en) METHOD FOR PRODUCING DIETHINE TETRACARBOXIMIDES
GB201208756D0 (en) Methods
GB201202098D0 (en) New process
GB201220686D0 (en) Methods
AP2012000550S (en) E-horn methods
GB201216074D0 (en) Methods
GB201209689D0 (en) Methods